Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform
Withdrawn before enrolling · Phase 3
Conditions studied: Severe Hemophilia A
In brief
This study will evaluate if Eloctate is superior to Emicizumab in reducing inhibitors in children with severe hemophilia when given before the first bleed (preemptive) and continued weekly to prevent bleeds (prophylaxis); and whether Eloctate immune tolerance induction (ITI) plus emicizumab is superior to Eloctate ITI alone in eradicating inhibitor formation in children and adults with severe hemophilia A.
Key facts
- Study ID
- NCT02196207
- Run by
- Margaret Ragni
- People needed
- 0
- Starts
- 2020-08-01
- Expected to finish
- 2027-07-01
- Last updated by the study team
- 2019-08-20
Who can join
Age: 0 and older, up to 99. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Hemophilia Center of Western Pennsylvania — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.